TG Therapeutics, Inc. logo TGTX - TG Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 1
SELL 1
STRONG
SELL 0
| PRICE TARGET: $54.50 DETAILS
HIGH: $70.00
LOW: $39.00
MEDIAN: $54.50
CONSENSUS: $54.50
UPSIDE: 40.21%

Stock News

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 27-29, 2026 in Charlotte, N.C. Abstracts are available on the CMSC website at http://www.mscare.org/2026 and data presentations are also available and can be accessed either on the 2026 CMSC meeting app or on TG's website at www.tgtherapeutics.com/publications. All TG data will be presented by the respective authors during the CMSC conference on Thursday, May 28th, 2026. Additional details of the presentation schedule can be found below.

May 26, 2026 03:30 AM • globenewswire.com
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S. net product revenue target to $885-900 million Conference call to be held today, Wednesday, May 6, 2026, at 8:30 AM ET NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S.

May 06, 2026 03:00 AM • globenewswire.com
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook

TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook

TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version's trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets.

Apr 18, 2026 06:32 PM • seekingalpha.com
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). BRIUMVI is currently approved in the United States and several ex-US territories as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in adults with RMS.

Apr 15, 2026 03:30 AM • globenewswire.com
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside

TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside

Briumvi's US net product revenues reached $182.7M in Q4'25, with 19.5% sequential growth, and 2026 global revenue guidance is $875M–$900M. Key catalysts include the ENHANCE trial readout (mid-2026) and pivotal subcutaneous Briumvi data (year-end 2026/1Q 2027), both with significant upside potential. TGTX's $300M buyback program could provide downside support, although material negative updates are still a risk even with the buyback program in place.

Mar 31, 2026 03:07 PM • seekingalpha.com
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.

1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.

Congress Asset Management Co. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,922,410 shares of the biopharmaceutical company's stock, valued at approximately $57,307,000. Congress Asset Management Co.

Mar 24, 2026 09:39 AM • defenseworld.net
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people with highly active relapsing forms of multiple sclerosis (RMS). The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Düsseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as ≥2 relapses in the year prior and ≥1 gadolinium-enhancing (Gd+) T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity (NEDA-3), with BRIUMVI compared to teriflunomide. Additional details from the publication are included below.

Mar 09, 2026 03:30 AM • globenewswire.com

Price Targets